This invention describes a new drug delivery system for improving cancer treatment via the local and sustained delivery of antibodies targeting immune checkpoints. It utilizes a local intradermal injection of in situ crosslinked hydrogel to tumor-draining lymph nodes in order to deliver immune checkpoint blockade antibodies and promote activation of t cells so that they can infiltrate the tumor microenvironment. Specifically, the Georgia Tech research team’s method mixes synthesized thiolated thermosensitive polymers with maleimide functionalized polyethylene glycol to make the hydrogel. The hydrogel is then combined with the antibody of interest before delivery.

In early experiments, this technology demonstrated reduced tumor growth, improved survival rates, and minimal liver toxicity. By promoting the differentiation, proliferation, and activation of tumor-specific t cells, the crosslinked hydrogel leverages the body’s immune system to augment the effects of antitumor treatments.